Founded in 2013, Jecho is a global biotechnology organization committed to advancing biopharmaceutical innovation through a fully integrated capabilities spanning early research to clinical development and manufacturing. With strategically located operations in the United States and China, Jecho combines scientific excellence, engineering strength, and regulatory expertise to bring transformative therapies to market.

At the forefront of biotherapeutics innovation, Jecho Labs in Frederick, Maryland, serves as the company’s R&D nucleus. This facility focuses on new product exploration and associated early-stage functions, including analytical and process development, and quality control. These capabilities form the scientific and technical foundation for Jecho’s pipeline.

Jecho Institute, located in Shanghai, China, bridges the gap between bench and bedside through its focus on translational research and technology platform development. With expertise in animal models and product/process optimization, the institute accelerates the refinement and validation of therapeutic candidates.

Jecho Bio in Tianjin, China, serves as the hub for GMP manufacturing and late-stage development within the company’s integrated pipeline. The facility is equipped to support both clinical-stage and commercial-scale production, meeting regulatory requirements from health authorities such as China’s CDE and the U.S. FDA.. Beyond manufacturing, the site manages essential studies—including toxicology and pharmacokinetic/pharmacodynamic (PK/PD) evaluations—that are critical for regulatory approval. Jecho Bio also plays a central role in designing and managing clinical trials and shaping regulatory submission strategies, ensuring a seamless transition from preclinical research to market authorization for the therapeutic candidates.

Together, these three facilities form a global network synergized to streamline the path from discovery to clinic, benefiting patients worldwide.